Table of Contents Author Guidelines Submit a Manuscript
Neural Plasticity
Volume 2017, Article ID 5012129, 15 pages
https://doi.org/10.1155/2017/5012129
Review Article

The Contribution of α-Synuclein Spreading to Parkinson’s Disease Synaptopathy

1Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
2IRCCS Fondazione Ospedale San Camillo (NHS-Italy), Venice Lido, Italy

Correspondence should be addressed to Arianna Bellucci; ti.sbinu@icculleb.annaira

Received 4 August 2016; Revised 11 November 2016; Accepted 22 November 2016; Published 3 January 2017

Academic Editor: Gabby Rudenko

Copyright © 2017 Francesca Longhena et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. N. Brose, V. O'Connor, and P. Skehel, “Synaptopathy: dysfunction of synaptic function?” Biochemical Society Transactions, vol. 38, no. 2, pp. 443–444, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Lepeta, M. V. Lourenco, B. C. Schweitzer et al., “Synaptopathies: synaptic dysfunction in neurological disorders—a review from students to students,” Journal of Neurochemistry, vol. 138, no. 6, pp. 785–805, 2016. View at Publisher · View at Google Scholar
  3. O. Anichtchik, L. Calo, and M. G. Spillantini, “Synaptic dysfunction in synucleinopathies,” CNS and Neurological Disorders—Drug Targets, vol. 12, no. 8, pp. 1094–1100, 2013. View at Google Scholar · View at Scopus
  4. M. Zaltieri, J. Grigoletto, F. Longhena et al., “α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons,” Journal of Cell Science, vol. 128, no. 13, pp. 2231–2243, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Calo, M. Wegrzynowicz, J. Santivañez-Perez, and M. Grazia Spillantini, “Synaptic failure and α-synuclein,” Movement Disorders, vol. 31, no. 2, pp. 169–177, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Bellucci, N. B. Mercuri, A. Venneri et al., “Review: Parkinson's disease: from synaptic loss to connectome dysfunction,” Neuropathology and Applied Neurobiology, vol. 42, no. 1, pp. 77–94, 2016. View at Publisher · View at Google Scholar
  7. J. P. Bolam and E. K. Pissadaki, “Living on the edge with too many mouths to feed: why dopamine neurons die,” Movement Disorders, vol. 27, no. 12, pp. 1478–1483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. I. Aldecoa, J. Navarro-Otano, N. Stefanova et al., “Alpha-synuclein immunoreactivity patterns in the enteric nervous system,” Neuroscience Letters, vol. 602, pp. 145–149, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Recasens, B. Dehay, J. Bové et al., “Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys,” Annals of Neurology, vol. 75, no. 3, pp. 351–362, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. H. Kordower, Y. Chu, R. A. Hauser, T. B. Freeman, and C. W. Olanow, “Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease,” Nature Medicine, vol. 14, no. 5, pp. 504–506, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. J. H. Kordower, Y. Chu, R. A. Hauser, C. W. Olanow, and T. B. Freeman, “Transplanted dopaminergic neurons develop PD pathologic changes: a second case report,” Movement Disorders, vol. 23, no. 16, pp. 2303–2306, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. W. Li, E. Englund, H. Widner et al., “Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 23, pp. 6544–6549, 2016. View at Publisher · View at Google Scholar
  13. G. G. Kovacs, L. Breydo, R. Green et al., “Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread,” Neurobiology of Disease, vol. 69, pp. 76–92, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Del Tredici and H. Braak, “Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology,” Neuropathology and Applied Neurobiology, vol. 42, no. 1, pp. 33–50, 2016. View at Publisher · View at Google Scholar
  16. J. M. George, “The synucleins,” Genome Biology, vol. 3, no. 1, 2002. View at Google Scholar
  17. A. Ulusoy and D. A. Di Monte, “α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications,” Molecular neurobiology, vol. 47, no. 2, pp. 484–494, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Ulusoy, R. E. Musgrove, R. Rusconi et al., “Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury,” Acta Neuropathologica Communications, vol. 3, no. 1, article 13, 2015. View at Publisher · View at Google Scholar
  19. F. Pan-Montojo, M. Schwarz, C. Winkler et al., “Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice,” Scientific Reports, vol. 2, article 898, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Svensson, E. Horváth-Puhó, R. W. Thomsen et al., “Vagotomy and subsequent risk of Parkinson's disease,” Annals of Neurology, vol. 78, no. 4, pp. 522–529, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Brundin, J. Ma, and J. H. Kordower, “How strong is the evidence that Parkinson's disease is a prion disorder?” Current Opinion in Neurology, vol. 29, no. 4, pp. 459–466, 2016. View at Publisher · View at Google Scholar
  22. M. E. Bernis, J. T. Babila, S. Breid, K. A. Wüsten, U. Wüllner, and G. Tamgüney, “Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein,” Acta Neuropathologica Communications, vol. 3, no. 1, article 75, 2015. View at Publisher · View at Google Scholar
  23. S. Breid, M. E. Bernis, J. T. Babila, M. C. Garza, H. Wille, and G. Tamgüney, “Neuroinvasion of α-synuclein prionoids after intraperitoneal and intraglossal inoculation,” Journal of Virology, vol. 90, no. 20, pp. 9182–9193, 2016. View at Publisher · View at Google Scholar
  24. S. B. Prusiner, A. L. Woerman, D. A. Mordes et al., “Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 38, pp. E5308–E5317, 2015. View at Publisher · View at Google Scholar · View at Scopus
  25. A. L. Woerman, J. Stöhr, A. Aoyagi et al., “Propagation of prions causing synucleinopathies in cultured cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 35, pp. E4949–E4958, 2015. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Stuendl, M. Kunadt, N. Kruse et al., “Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson’s disease and dementia with Lewy bodies,” Brain, vol. 139, no. 2, pp. 481–494, 2016. View at Publisher · View at Google Scholar
  27. K. M. Danzer, S. K. Krebs, M. Wolff, G. Birk, and B. Hengerer, “Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology,” Journal of Neurochemistry, vol. 111, no. 1, pp. 192–203, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. E. Angot, J. A. Steiner, C. Hansen, J.-Y. Li, and P. Brundin, “Are synucleinopathies prion-like disorders?” The Lancet Neurology, vol. 9, no. 11, pp. 1128–1138, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. C. W. Olanow and P. Brundin, “Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?” Movement Disorders, vol. 28, no. 1, pp. 31–40, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C. L. Ugalde, D. I. Finkelstein, V. A. Lawson, and A. F. Hill, “Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers,” Journal of Neurochemistry, vol. 139, no. 2, pp. 162–180, 2016. View at Publisher · View at Google Scholar
  31. M. Iljina, G. A. Garcia, M. H. Horrocks et al., “Kinetic model of the aggregation of alpha-synuclein provides insights into prion-like spreading,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 9, pp. E1206–E1215, 2016. View at Publisher · View at Google Scholar
  32. E. Emmanouilidou and K. Vekrellis, “Exocytosis and spreading of normal and aberrant α-synuclein,” Brain Pathology, vol. 26, no. 3, pp. 398–403, 2016. View at Publisher · View at Google Scholar
  33. H.-J. Lee, S. Patel, and S.-J. Lee, “Intravesicular localization and exocytosis of α-synuclein and its aggregates,” The Journal of Neuroscience, vol. 25, no. 25, pp. 6016–6024, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Maroteaux, J. T. Campanelli, and R. H. Scheller, “Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal,” Journal of Neuroscience, vol. 8, no. 8, pp. 2804–2815, 1988. View at Google Scholar · View at Scopus
  35. K. Wakabayashi, F. Mori, K. Tanji, S. Orimo, and H. Takahashi, “Involvement of the peripheral nervous system in synucleinopathies, tauopathies and other neurodegenerative proteinopathies of the brain,” Acta Neuropathologica, vol. 120, no. 1, pp. 1–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Braak and K. Del Tredici, “Invited Article: nervous system pathology in sporadic Parkinson disease,” Neurology, vol. 70, no. 20, pp. 1916–1925, 2008. View at Google Scholar
  37. M. Böttner, T. Fricke, M. Müller et al., “Alpha-synuclein is associated with the synaptic vesicle apparatus in the human and rat enteric nervous system,” Brain Research, vol. 1614, pp. 51–59, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Totterdell, D. Hanger, and G. E. Meredith, “The ultrastructural distribution of alpha-synuclein-like protein in normal mouse brain,” Brain Research, vol. 1004, no. 1-2, pp. 61–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. S. L. Gordon and M. A. Cousin, “The sybtraps: control of synaptobrevin traffic by synaptophysin, α-synuclein and AP-180,” Traffic, vol. 15, no. 3, pp. 245–254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. B. Butler, K. Saha, T. Rana et al., “Dopamine transporter activity is modulated by α-synuclein,” The Journal of Biological Chemistry, vol. 290, no. 49, pp. 29542–29554, 2015. View at Publisher · View at Google Scholar · View at Scopus
  41. A. Bellucci, G. Collo, I. Sarnico, L. Battistin, C. Missale, and P. Spano, “Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation,” Journal of Neurochemistry, vol. 106, no. 2, pp. 560–577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Bellucci, L. Navarria, E. Falarti et al., “Redistribution of DAT/α-synuclein complexes visualized by ‘in situ’ proximity ligation assay in transgenic mice modelling early Parkinson's disease,” PLoS ONE, vol. 6, no. 12, Article ID e27959, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. D. Gitler, B. J. Bevis, J. Shorter et al., “The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 1, pp. 145–150, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. Y. Chen and J. Lippincott-Schwartz, “Rab10 delivers GLUT4 storage vesicles to the plasma membrane,” Communicative and Integrative Biology, vol. 6, no. 3, Article ID e23779, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Fusco, A. De Simone, T. Gopinath et al., “Direct observation of the three regions in α-synuclein that determine its membrane-bound behaviour,” Nature Communications, vol. 5, article 3827, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Fusco, A. De Simone, P. Arosio, M. Vendruscolo, G. Veglia, and C. M. Dobson, “Structural ensembles of membrane-bound α-synuclein reveal the molecular determinants of synaptic vesicle affinity,” Scientific Reports, vol. 6, Article ID 27125, 2016. View at Publisher · View at Google Scholar
  47. V. V. Shvadchak, D. A. Yushchenko, R. Pievo, and T. M. Jovin, “The mode of α-synuclein binding to membranes depends on lipid composition and lipid to protein ratio,” FEBS Letters, vol. 585, no. 22, pp. 3513–3519, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. S.-I. Kubo, V. M. Nemani, R. J. Chalkley et al., “A combinatorial code for the interaction of α-synuclein with membranes,” The Journal of Biological Chemistry, vol. 280, no. 36, pp. 31664–31672, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Burré, M. Sharma, and T. C. Südhof, “Definition of a molecular pathway mediating α-synuclein neurotoxicity,” Journal of Neuroscience, vol. 35, no. 13, pp. 5221–5232, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. G. T. Corbett and J. H. Kordower, “The native form of α-Synuclein: monomer, tetramer, or a combination in equilibrium,” Movement Disorders, vol. 30, no. 14, pp. 1870–1870, 2015. View at Publisher · View at Google Scholar · View at Scopus
  51. U. Dettmer, A. J. Newman, F. Soldner et al., “Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation,” Nature Communications, vol. 6, p. 7314, 2015. View at Publisher · View at Google Scholar
  52. K. K. Sahu, M. T. Woodside, and J. A. Tuszynski, “α-synuclein dimer structures found from computational simulations,” Biochimie, vol. 116, pp. 133–140, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. N. Lorenzen, L. Lemminger, J. N. Pedersen, S. B. Nielsen, and D. E. Otzen, “The N-terminus of α-synuclein is essential for both monomeric and oligomeric interactions with membranes,” FEBS Letters, vol. 588, no. 3, pp. 497–502, 2014. View at Publisher · View at Google Scholar · View at Scopus
  54. Z. Jiang, S. K. Hess, F. Heinrich, and J. C. Lee, “Molecular details of α-synuclein membrane association revealed by neutrons and photons,” Journal of Physical Chemistry B, vol. 119, no. 14, pp. 4812–4823, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Pirc and N. P. Ulrih, “α-Synuclein interactions with phospholipid model membranes: key roles for electrostatic interactions and lipid-bilayer structure,” Biochimica et Biophysica Acta—Biomembranes, vol. 1848, no. 10, pp. 2002–2012, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. O. M. El-Agnaf, S. A. Salem, K. E. Paleologou et al., “α-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma,” The FASEB Journal, vol. 17, no. 13, pp. 1945–1947, 2003. View at Publisher · View at Google Scholar
  57. O. M. A. El-Agnaf, S. A. Salem, K. E. Paleologou et al., “Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease,” The FASEB Journal, vol. 20, no. 3, pp. 419–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Tokuda, S. A. Salem, D. Allsop et al., “Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease,” Biochemical and Biophysical Research Communications, vol. 349, no. 1, pp. 162–166, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. I. Devic, H. Hwang, J. S. Edgar et al., “Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease,” Brain, vol. 134, p. e178, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. J.-Y. Li, E. Englund, J. L. Holton et al., “Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation,” Nature Medicine, vol. 14, no. 5, pp. 501–503, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. S. K. Lee, R. V. Sillitoe, C. Silva, M. Martina, and G. Sekerkova, “α-Synuclein expression in the mouse cerebellum is restricted to VGluT1 excitatory terminals and is enriched in unipolar brush cells,” Cerebellum, vol. 14, no. 5, pp. 516–527, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. A. Jang, H.-J. Lee, J.-E. Suk, J.-W. Jung, K.-P. Kim, and S.-J. Lee, “Non-classical exocytosis of α-synuclein is sensitive to folding states and promoted under stress conditions,” Journal of Neurochemistry, vol. 113, no. 5, pp. 1263–1274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. E. Emmanouilidou, K. Melachroinou, T. Roumeliotis et al., “Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival,” The Journal of Neuroscience, vol. 30, no. 20, pp. 6838–6851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Alvarez-Erviti, Y. Seow, A. H. Schapira et al., “Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission,” Neurobiology of Disease, vol. 42, no. 3, pp. 360–367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. M. G. Stokholm, E. H. Danielsen, S. J. Hamilton-Dutoit, and P. Borghammer, “Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients,” Annals of Neurology, vol. 79, no. 6, pp. 940–949, 2016. View at Publisher · View at Google Scholar
  66. K. M. Shannon, A. Keshavarzian, E. Mutlu et al., “Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease,” Movement Disorders, vol. 27, no. 6, pp. 709–715, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. R. J. Phillips, G. C. Walter, S. L. Wilder, E. A. Baronowsky, and T. L. Powley, “Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease?” Neuroscience, vol. 153, no. 3, pp. 733–750, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. V. Donadio, A. Incensi, V. Leta et al., “Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson diseasee,” Neurology, vol. 82, no. 15, pp. 1362–1369, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. K. Doppler, S. Ebert, N. Üçeyler et al., “Cutaneous neuropathy in Parkinson's disease: a window into brain pathology,” Acta Neuropathologica, vol. 128, no. 1, pp. 99–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Gelpi, J. Navarro-Otano, E. Tolosa et al., “Multiple organ involvement by alpha-synuclein pathology in lewy body disorders,” Movement Disorders, vol. 29, no. 8, pp. 1010–1018, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. M. G. Cersosimo and E. E. Benarroch, “Pathological correlates of gastrointestinal dysfunction in Parkinson's disease,” Neurobiology of Disease, vol. 46, no. 3, pp. 559–564, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. D. M. A. Mann and P. O. Yates, “Pathological basis for neurotransmitter changes in Parkinson's disease,” Neuropathology and Applied Neurobiology, vol. 9, no. 1, pp. 3–19, 1983. View at Publisher · View at Google Scholar · View at Scopus
  73. J. G. Greene, “Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease,” Antioxidants & Redox Signaling, vol. 21, no. 4, pp. 649–667, 2014. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Sumikura, M. Takao, H. Hatsuta et al., “Distribution of α-synuclein in the spinal cord and dorsal root ganglia in an autopsy cohort of elderly persons,” Acta Neuropathologica Communications, vol. 3, article 57, 2015. View at Publisher · View at Google Scholar
  75. C. H. Hawkes, “Parkinson's disease and aging: same or different process?” Movement Disorders, vol. 23, no. 1, pp. 47–53, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. A. S. Buchman, J. M. Shulman, S. Nag et al., “Nigral pathology and parkinsonian signs in elders without Parkinson disease,” Annals of Neurology, vol. 71, no. 2, pp. 258–266, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. A. S. Buchman, L. Yu, R. S. Wilson, J. A. Schneider, and D. A. Bennett, “Association of brain pathology with the progression of frailty in older adults,” Neurology, vol. 80, no. 22, pp. 2055–2061, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. N. J. Diederich and A. Parent, “Parkinson's disease: acquired frailty of archaic neural networks?” Journal of the Neurological Sciences, vol. 314, no. 1-2, pp. 143–151, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. M. E. Kalaitzakis, M. B. Graeber, S. M. Gentleman, and R. K. B. Pearce, “The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging,” Neuropathology and Applied Neurobiology, vol. 34, no. 3, pp. 284–295, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. G. M. Halliday and H. McCann, “The progression of pathology in Parkinson's disease,” Annals of the New York Academy of Sciences, vol. 1184, pp. 188–195, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. X. Wang, S. Yu, F. Li, and T. Feng, “Detection of α-synuclein oligomers in red blood cells as a potential biomarker of Parkinson's disease,” Neuroscience Letters, vol. 599, pp. 115–119, 2015. View at Publisher · View at Google Scholar · View at Scopus
  82. T. Tokuda, M. M. Qureshi, M. T. Ardah et al., “Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease,” Neurology, vol. 75, no. 20, pp. 1766–1772, 2010. View at Publisher · View at Google Scholar · View at Scopus
  83. S. Kim, B. S. Jeon, C. Heo et al., “α-Synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease,” FASEB Journal, vol. 18, no. 13, pp. 1615–1617, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Shi, C. Liu, T. J. Cook et al., “Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson's disease,” Acta Neuropathologica, vol. 128, no. 5, pp. 639–650, 2014. View at Publisher · View at Google Scholar · View at Scopus
  85. G. K. Joshi, S. Deitz-McElyea, T. Liyanage et al., “Label-free nanoplasmonic-based short noncoding RNA sensing at attomolar concentrations allows for quantitative and highly specific assay of microRNA-10b in biological fluids and circulating exosomes,” ACS Nano, vol. 9, no. 11, pp. 11075–11089, 2015. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Stuendl, M. Kunadt, N. Kruse et al., “Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies,” Brain, vol. 139, part 2, pp. 481–494, 2016. View at Publisher · View at Google Scholar
  87. P. Salahuddin, M. T. Fatima, A. S. Abdelhameed, S. Nusrat, and R. H. Khan, “ChemInform abstract: structure of amyloid oligomers and their mechanisms of toxicities: targeting amyloid oligomers using novel therapeutic approaches,” ChemInform, vol. 47, no. 22, 2016. View at Publisher · View at Google Scholar
  88. A. Villar-Piqué, T. L. da Fonseca, and T. F. Outeiro, “Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies,” Journal of Neurochemistry, vol. 139, no. 1, pp. 240–255, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. W. Peelaerts, L. Bousset, A. Van der Perren et al., “α-Synuclein strains cause distinct synucleinopathies after local and systemic administration,” Nature, vol. 522, no. 7556, pp. 340–344, 2015. View at Publisher · View at Google Scholar · View at Scopus
  90. J.-Y. Park, S. R. Paik, I. Jou, and S. M. Park, “Microglial phagocytosis is enhanced by monomeric α-synuclein, not aggregated α-synuclein: implications for Parkinson's disease,” Glia, vol. 56, no. 11, pp. 1215–1223, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. K. S. Kim, J. S. Kim, J.-Y. Park et al., “DJ-1 associates with lipid rafts by palmitoylation and regulates lipid rafts-dependent endocytosis in astrocytes,” Human Molecular Genetics, vol. 22, no. 23, pp. 4805–4817, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Hoffmann, B. Ettle, A. Bruno et al., “Alpha-synuclein activates BV2 microglia dependent on its aggregation state,” Biochemical and Biophysical Research Communications, vol. 479, no. 4, pp. 881–886, 2016. View at Publisher · View at Google Scholar
  93. W. Zhang, T. Wang, Z. Pei et al., “Aggregated α-synuclein activates microglia: a process leading to disease progression in Parkinson's disease,” The FASEB Journal, vol. 19, no. 6, pp. 533–542, 2005. View at Publisher · View at Google Scholar · View at Scopus
  94. J. H. Lee, J. Ying, and A. Bax, “Nuclear magnetic resonance observation of α-synuclein membrane interaction by monitoring the acetylation reactivity of its lysine side chains,” Biochemistry, vol. 55, no. 35, pp. 4949–4959, 2016. View at Publisher · View at Google Scholar
  95. P. J. Salveson, R. K. Spencer, and J. S. Nowick, “X-ray crystallographic structure of oligomers formed by a toxic β-hairpin derived from α-synuclein: trimers and higher-order oligomers,” Journal of the American Chemical Society, vol. 138, no. 13, pp. 4458–4467, 2016. View at Publisher · View at Google Scholar
  96. S. W. Chen, S. Drakulic, E. Deas et al., “Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 16, pp. E1994–E2003, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Roostaee, S. Beaudoin, A. Staskevicius, and X. Roucou, “Aggregation and neurotoxicity of recombinant α-synuclein aggregates initiated by dimerization,” Molecular Neurodegeneration, vol. 8, article 5, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. I. F. Tsigelny, Y. Sharikov, W. Wrasidlo et al., “Role of α-synuclein penetration into the membrane in the mechanisms of oligomer pore formation,” FEBS Journal, vol. 279, no. 6, pp. 1000–1013, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Winner, R. Jappelli, S. K. Maji et al., “In vivo demonstration that α-synuclein oligomers are toxic,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 10, pp. 4194–4199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. S. Celej, R. Sarroukh, E. Goormaghtigh, G. D. Fidelio, J.-M. Ruysschaert, and V. Raussens, “Toxic prefibrillar α-synuclein amyloid oligomers adopt a distinctive antiparallel β-sheet structure,” Biochemical Journal, vol. 443, no. 3, pp. 719–726, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. N. Plotegher, E. Gratton, and L. Bubacco, “Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells,” Biochimica et Biophysica Acta (BBA)—General Subjects, vol. 1840, no. 6, pp. 2014–2024, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. S. R. Subramaniam, L. Vergnes, N. R. Franich, K. Reue, and M.-F. Chesselet, “Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein,” Neurobiology of Disease, vol. 70, pp. 204–213, 2014. View at Publisher · View at Google Scholar · View at Scopus
  103. E. S. Luth, I. G. Stavrovskaya, T. Bartels, B. S. Kristal, and D. J. Selkoe, “Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction,” Journal of Biological Chemistry, vol. 289, no. 31, pp. 21490–21507, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. A. N. D. Stefanovic, M. T. Stöckl, M. M. A. E. Claessens, and V. Subramaniam, “α-Synuclein oligomers distinctively permeabilize complex model membranes,” The FEBS Journal, vol. 281, no. 12, pp. 2838–2850, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. B. J. Ryan, S. Hoek, E. A. Fon, and R. Wade-Martins, “Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease,” Trends in Biochemical Sciences, vol. 40, no. 4, pp. 200–210, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Mullin and A. Schapira, “α-Synuclein and mitochondrial dysfunction in Parkinson's disease,” Molecular neurobiology, vol. 47, no. 2, pp. 587–597, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. M. Zaltieri, F. Longhena, M. Pizzi, C. Missale, P. Spano, and A. Bellucci, “Mitochondrial dysfunction and α-synuclein synaptic pathology in Parkinson's disease: who's on first?” Parkinson's Disease, vol. 2015, Article ID 108029, 10 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  108. E. Colla, P. H. Jensen, O. Pletnikova, J. C. Troncoso, C. Glabe, and M. K. Lee, “Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo,” Journal of Neuroscience, vol. 32, no. 10, pp. 3301–3305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. A. Bellucci, L. Navarria, M. Zaltieri et al., “Induction of the unfolded protein response by α-synuclein in experimental models of Parkinson's disease,” Journal of Neurochemistry, vol. 116, no. 4, pp. 588–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Deas, N. Cremades, P. R. Angelova et al., “Alpha-synuclein oligomers interact with metal ions to induce oxidative stress and neuronal death in Parkinson's disease,” Antioxidants & Redox Signaling, vol. 24, no. 7, pp. 376–391, 2016. View at Publisher · View at Google Scholar
  111. E. Rockenstein, S. Nuber, C. R. Overk et al., “Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo,” Brain, vol. 137, no. 5, pp. 1496–1513, 2014. View at Publisher · View at Google Scholar · View at Scopus
  112. T. J. Kaufmann, P. M. Harrison, M. J. Richardson, T. J. Pinheiro, and M. J. Wall, “Intracellular soluble α-synuclein oligomers reduce pyramidal cell excitability,” The Journal of Physiology, vol. 594, no. 10, pp. 2751–2772, 2016. View at Publisher · View at Google Scholar
  113. M. J. Diógenes, R. B. Dias, D. M. Rombo et al., “Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation,” Journal of Neuroscience, vol. 32, no. 34, pp. 11750–11762, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. M. Emanuele, A. Esposito, S. Camerini et al., “Exogenous alpha-synuclein alters pre- and post-synaptic activity by fragmenting lipid rafts,” EBioMedicine, vol. 7, pp. 191–204, 2016. View at Publisher · View at Google Scholar
  115. H. L. Roberts and D. R. Brown, “Seeking a mechanism for the toxicity of oligomeric α-synuclein,” Biomolecules, vol. 5, no. 2, pp. 282–305, 2015. View at Publisher · View at Google Scholar
  116. J. M. Fearnley and A. J. Lees, “Ageing and Parkinson's disease: substantia nigra regional selectivity,” Brain, vol. 114, no. 5, pp. 2283–2301, 1991. View at Publisher · View at Google Scholar · View at Scopus
  117. G. M. Halliday, D. A. McRitchie, H. Cartwright, R. Pamphlett, M. A. Hely, and J. G. L. Morris, “Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease,” Journal of Clinical Neuroscience, vol. 3, no. 1, pp. 52–60, 1996. View at Publisher · View at Google Scholar · View at Scopus
  118. L. L. Venda, S. J. Cragg, V. L. Buchman, and R. Wade-Martins, “α-Synuclein and dopamine at the crossroads of Parkinson's disease,” Trends in Neurosciences, vol. 33, no. 12, pp. 559–568, 2010. View at Publisher · View at Google Scholar · View at Scopus
  119. K. A. Conway, J.-C. Rochet, R. M. Bieganski, and P. T. Lansbury Jr., “Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct,” Science, vol. 294, no. 5545, pp. 1346–1349, 2001. View at Publisher · View at Google Scholar · View at Scopus
  120. A. Rekas, R. B. Knott, A. Sokolova et al., “The structure of dopamine induced α-synuclein oligomers,” European Biophysics Journal, vol. 39, no. 10, pp. 1407–1419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Follmer, E. Coelho-Cerqueira, D. Y. Yatabe-Franco et al., “Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of α-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL),” Journal of Biological Chemistry, vol. 290, no. 46, pp. 27660–27679, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. C. C. Curtain, N. M. Kirby, H. D. T. Mertens et al., “Alpha-synuclein oligomers and fibrils originate in two distinct conformer pools: A Small Angle X-Ray Scattering And Ensemble Optimisation Modelling Study,” Molecular BioSystems, vol. 11, no. 1, pp. 190–196, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. L. R. Lemkau, G. Comellas, S. W. Lee et al., “Site-specific perturbations of alpha-synuclein fibril structure by the Parkinson's disease associated mutations A53T and E46K,” PLoS ONE, vol. 8, no. 3, Article ID e49750, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. R. Harada, N. Kobayashi, J. Kim et al., “The effect of amino acid substitution in the imperfect repeat sequences of α-synuclein on fibrillation,” Biochimica et Biophysica Acta, vol. 1792, no. 10, pp. 998–1003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  125. J. W. Kelly, “The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways,” Current Opinion in Structural Biology, vol. 8, no. 1, pp. 101–106, 1998. View at Publisher · View at Google Scholar · View at Scopus
  126. K. Ono and M. Yamada, “Low-n oligomers as therapeutic targets of Alzheimer's disease,” Journal of Neurochemistry, vol. 117, no. 1, pp. 19–28, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. L. C. Serpell, J. Berriman, R. Jakes, M. Goedert, and R. A. Crowther, “Fiber diffraction of synthetic α-synuclein filaments shows amyloid-like cross-β conformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4897–4902, 2000. View at Publisher · View at Google Scholar · View at Scopus
  128. V. V. Shvadchak and V. Subramaniam, “A four-amino acid linker between repeats in the α-synuclein sequence is important for fibril formation,” Biochemistry, vol. 53, no. 2, pp. 279–281, 2014. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Izawa, H. Tateno, H. Kameda et al., “Role of C-terminal negative charges and tyrosine residues in fibril formation of α-synuclein,” Brain and Behavior, vol. 2, no. 5, pp. 595–605, 2012. View at Publisher · View at Google Scholar · View at Scopus
  130. K. Levitan, D. Chereau, S. I. A. Cohen et al., “Conserved C-terminal charge exerts a profound influence on the aggregation rate of α-synuclein,” Journal of Molecular Biology, vol. 411, no. 2, pp. 329–333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. E. Jo, J. McLaurin, C. M. Yip, P. St George-Hyslop, and P. E. Fraser, “α-Synuclein membrane interactions and lipid specificity,” Journal of Biological Chemistry, vol. 275, no. 44, pp. 34328–34334, 2000. View at Publisher · View at Google Scholar · View at Scopus
  132. I. F. Tsigelny, Y. Sharikov, M. A. Miller, and E. Masliah, “Mechanism of alpha-synuclein oligomerization and membrane interaction: theoretical approach to unstructured proteins studies,” Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 4, no. 4, pp. 350–357, 2008. View at Publisher · View at Google Scholar · View at Scopus
  133. K. M. Danzer, D. Haasen, A. R. Karow et al., “Different species of α-synuclein oligomers induce calcium influx and seeding,” The Journal of Neuroscience, vol. 27, no. 34, pp. 9220–9232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  134. B. Caughey and P. T. Lansbury Jr., “Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders,” Annual Review of Neuroscience, vol. 26, pp. 267–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  135. H. T. Lam, M. C. Graber, K. A. Gentry, and J. Bieschke, “Stabilization of α-synuclein fibril clusters prevents fragmentation and reduces seeding activity and toxicity,” Biochemistry, vol. 55, no. 4, pp. 675–685, 2016. View at Publisher · View at Google Scholar · View at Scopus
  136. V. Narayanan and S. Scarlata, “Membrane binding and self-association of α-synucleins,” Biochemistry, vol. 40, no. 33, pp. 9927–9934, 2001. View at Publisher · View at Google Scholar · View at Scopus
  137. H.-J. Lee, C. Choi, and S.-J. Lee, “Membrane-bound α-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form,” The Journal of Biological Chemistry, vol. 277, no. 1, pp. 671–678, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. J. Burré, “The synaptic function of α-synuclein,” Journal of Parkinson's Disease, vol. 5, no. 4, pp. 699–713, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Zhu and A. L. Fink, “Lipid binding inhibits α-synuclein fibril formation,” Journal of Biological Chemistry, vol. 278, no. 19, pp. 16873–16877, 2003. View at Publisher · View at Google Scholar · View at Scopus
  140. C. Hansen, E. Angot, A.-L. Bergström et al., “α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells,” Journal of Clinical Investigation, vol. 121, no. 2, pp. 715–725, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. J. H. Kordower, H. B. Dodiya, A. M. Kordower et al., “Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat,” Neurobiology of Disease, vol. 43, no. 3, pp. 552–557, 2011. View at Publisher · View at Google Scholar · View at Scopus
  142. E. Angot, J. A. Steiner, C. M. Tomé et al., “α-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo,” PLoS ONE, vol. 7, no. 6, Article ID e39465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  143. C. Dixon, N. Mathias, R. M. Zweig, D. A. Davis, and D. S. Gross, “α-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast,” Genetics, vol. 170, no. 1, pp. 47–59, 2005. View at Publisher · View at Google Scholar · View at Scopus
  144. D. C. Rubinsztein, “The roles of intracellular protein-degradation pathways in neurodegeneration,” Nature, vol. 443, no. 7113, pp. 780–786, 2006. View at Publisher · View at Google Scholar · View at Scopus
  145. T. Pan, S. Kondo, W. Le, and J. Jankovic, “The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease,” Brain, vol. 131, no. 8, pp. 1969–1978, 2008. View at Publisher · View at Google Scholar · View at Scopus
  146. G. K. Tofaris, R. Layfield, and M. G. Spillantini, “α-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome,” FEBS Letters, vol. 509, no. 1, pp. 22–26, 2001. View at Publisher · View at Google Scholar · View at Scopus
  147. K. E. Larsen and D. Sulzer, “Autophagy in neurons: a review,” Histology and Histopathology, vol. 17, no. 3, pp. 897–908, 2002. View at Google Scholar · View at Scopus
  148. K. S. P. McNaught, R. Belizaire, O. Isacson, P. Jenner, and C. W. Olanow, “Altered proteasomal function in sporadic Parkinson's disease,” Experimental Neurology, vol. 179, no. 1, pp. 38–46, 2003. View at Publisher · View at Google Scholar · View at Scopus
  149. C. W. Olanow and K. S. P. McNaught, “Ubiquitin-proteasome system and Parkinson's disease,” Movement Disorders, vol. 21, no. 11, pp. 1806–1823, 2006. View at Publisher · View at Google Scholar · View at Scopus
  150. G. K. Tofaris, A. Razzaq, B. Ghetti, K. S. Lilley, and M. G. Spillantini, “Ubiquitination of α-synuclein in lewy bodies is a pathological event not associated with impairment of proteasome function,” Journal of Biological Chemistry, vol. 278, no. 45, pp. 44405–44411, 2003. View at Publisher · View at Google Scholar · View at Scopus
  151. A. M. Cuervo, “Autophagy: many paths to the same end,” Molecular and Cellular Biochemistry, vol. 263, no. 1, pp. 55–72, 2004. View at Publisher · View at Google Scholar · View at Scopus
  152. G. E. Meredith, S. Totterdell, E. Petroske, K. Santa Cruz, R. C. Callison Jr., and Y.-S. Lau, “Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease,” Brain Research, vol. 956, no. 1, pp. 156–165, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. J. N. Keller, E. Dimayuga, Q. Chen, J. Thorpe, J. Gee, and Q. Ding, “Autophagy, proteasomes, lipofuscin, and oxidative stress in the aging brain,” International Journal of Biochemistry and Cell Biology, vol. 36, no. 12, pp. 2376–2391, 2004. View at Publisher · View at Google Scholar · View at Scopus
  154. M. Martinez-Vicente, G. Sovak, and A. M. Cuervo, “Protein degradation and aging,” Experimental Gerontology, vol. 40, no. 8-9, pp. 622–633, 2005. View at Publisher · View at Google Scholar · View at Scopus
  155. R. Kiffin, S. Kaushik, M. Zeng et al., “Altered dynamics of the lysosomal receptor for chaperone-mediated autophagy with age,” Journal of Cell Science, vol. 120, no. 5, pp. 782–791, 2007. View at Publisher · View at Google Scholar · View at Scopus
  156. J. F. Reyes, T. T. Olsson, J. T. Lamberts, M. J. Devine, T. Kunath, and P. Brundin, “A cell culture model for monitoring α-synuclein cell-to-cell transfer,” Neurobiology of Disease, vol. 77, pp. 266–275, 2015. View at Publisher · View at Google Scholar · View at Scopus
  157. L. Alvarez-Erviti, Y. Seow, H. Yin, C. Betts, S. Lakhal, and M. J. A. Wood, “Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes,” Nature Biotechnology, vol. 29, no. 4, pp. 341–345, 2011. View at Publisher · View at Google Scholar · View at Scopus
  158. J. Liu, J.-P. Zhang, M. Shi et al., “Rab11a and HSP90 regulate recycling of extracellular α-synuclein,” Journal of Neuroscience, vol. 29, no. 5, pp. 1480–1485, 2009. View at Publisher · View at Google Scholar · View at Scopus
  159. F. J. Verweij, J. M. Middeldorp, and D. M. Pegtel, “Intracellular signaling controlled by the endosomal-exosomal pathway,” Communicative & Integrative Biology, vol. 5, no. 1, pp. 88–93, 2014. View at Publisher · View at Google Scholar
  160. M. Kunadt, K. Eckermann, A. Stuendl et al., “Extracellular vesicle sorting of α-Synuclein is regulated by sumoylation,” Acta Neuropathologica, vol. 129, no. 5, pp. 695–713, 2015. View at Publisher · View at Google Scholar · View at Scopus
  161. A. Lo Cicero, P. D. Stahl, and G. Raposo, “Extracellular vesicles shuffling intercellular messages: for good or for bad,” Current Opinion in Cell Biology, vol. 35, pp. 69–77, 2015. View at Publisher · View at Google Scholar · View at Scopus
  162. C. Théry, L. Zitvogel, and S. Amigorena, “Exosomes: composition, biogenesis and function,” Nature Reviews Immunology, vol. 2, no. 8, pp. 569–579, 2002. View at Google Scholar · View at Scopus
  163. T. Hasegawa, M. Konno, T. Baba et al., “The AAA-ATPase VPS4 regulates extracellular secretion and lysosomal targeting of α-synuclein,” PLoS ONE, vol. 6, no. 12, Article ID e29460, 2011. View at Publisher · View at Google Scholar · View at Scopus
  164. K. C. Luk, V. Kehm, J. Carroll et al., “Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice,” Science, vol. 338, no. 6109, pp. 949–953, 2012. View at Publisher · View at Google Scholar · View at Scopus
  165. J. G. Marblestone, S. C. Edavettal, Y. Lim, P. Lim, X. Zuo, and T. R. Butt, “Comparison of SUMO fusion technology with traditional gene fusion systems: enhanced expression and solubility with SUMO,” Protein Science, vol. 15, no. 1, pp. 182–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  166. T. Panavas, C. Sanders, and T. R. Butt, “SUMO fusion technology for enhanced protein production in prokaryotic and eukaryotic expression systems,” Methods in Molecular Biology, vol. 497, pp. 303–317, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. K. K. K. Chung, Y. Zhang, K. L. Lim et al., “Parkin ubiquitinates the α-synuclein−interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease,” Nature Medicine, vol. 7, no. 10, pp. 1144–1150, 2001. View at Publisher · View at Google Scholar · View at Scopus
  168. N. Sharma, P. J. McLean, H. Kawamata, M. C. Irizarry, and B. T. Hyman, “Alpha-synuclein has an altered conformation and shows a tight intermolecular interaction with ubiquitin in Lewy bodies,” Acta Neuropathologica, vol. 102, no. 4, pp. 329–334, 2001. View at Google Scholar · View at Scopus
  169. H.-J. Lee, J.-E. Suk, E.-J. Bae, J.-H. Lee, S. R. Paik, and S.-J. Lee, “Assembly-dependent endocytosis and clearance of extracellular α-synuclein,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 9, pp. 1835–1849, 2008. View at Publisher · View at Google Scholar · View at Scopus
  170. R. Rott, R. Szargel, J. Haskin et al., “Monoubiquitylation of α-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells,” Journal of Biological Chemistry, vol. 283, no. 6, pp. 3316–3328, 2008. View at Publisher · View at Google Scholar · View at Scopus
  171. W. J. Schulz-Schaeffer, “The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia,” Acta Neuropathologica, vol. 120, no. 2, pp. 131–143, 2010. View at Publisher · View at Google Scholar · View at Scopus
  172. K. C. Luk, V. M. Kehm, B. Zhang, P. O'Brien, J. Q. Trojanowski, and V. M. Y. Lee, “Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice,” Journal of Experimental Medicine, vol. 209, no. 5, pp. 975–988, 2012. View at Publisher · View at Google Scholar · View at Scopus
  173. M. Masuda-Suzukake, T. Nonaka, M. Hosokawa et al., “Prion-like spreading of pathological α-synuclein in brain,” Brain, vol. 136, part 4, pp. 1128–1138, 2013. View at Publisher · View at Google Scholar · View at Scopus
  174. M. Masuda-Suzukake, T. Nonaka, M. Hosokawa et al., “Pathological alpha-synuclein propagates through neural networks,” Acta Neuropathologica Communications, vol. 2, article no. 88, 2014. View at Publisher · View at Google Scholar · View at Scopus
  175. A. N. Sacino, M. Brooks, A. B. McKinney et al., “Brain injection of α-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker,” The Journal of Neuroscience, vol. 34, no. 37, pp. 12368–12378, 2014. View at Publisher · View at Google Scholar · View at Scopus
  176. A. Tarutani, G. Suzuki, A. Shimozawa et al., “The effect of fragmented pathogenic α-synuclein seeds on prion-like propagation,” Journal of Biological Chemistry, vol. 291, no. 36, pp. 18675–18688, 2016. View at Publisher · View at Google Scholar
  177. M. Helwig, M. Klinkenberg, R. Rusconi et al., “Brain propagation of transduced α-synuclein involves non-fibrillar protein species and is enhanced in α-synuclein null mice,” Brain, vol. 139, part 3, pp. 856–870, 2016. View at Publisher · View at Google Scholar
  178. K. M. Danzer, L. R. Kranich, W. P. Ruf et al., “Exosomal cell-to-cell transmission of alpha synuclein oligomers,” Molecular Neurodegeneration, vol. 7, no. 1, article 42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  179. E. Illes-Toth, M. R. Ramos, R. Cappai, C. Dalton, and D. P. Smith, “Distinct higher-order α -synuclein oligomers induce intracellular aggregation,” Biochemical Journal, vol. 468, no. 3, pp. 485–493, 2015. View at Publisher · View at Google Scholar · View at Scopus
  180. H. Chadchankar, J. Ihalainen, H. Tanila, and L. Yavich, “Decreased reuptake of dopamine in the dorsal striatum in the absence of alpha-synuclein,” Brain Research, vol. 1382, pp. 37–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  181. S. Liu, M. Fa, I. Ninan, F. Trinchese, W. Dauer, and O. Arancio, “α-Synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII,” European Journal of Neuroscience, vol. 25, no. 12, pp. 3583–3596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  182. A. Bellucci, L. Navarria, M. Zaltieri, C. Missale, and P. Spano, “Alpha-synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease,” Brain Research, vol. 1432, pp. 95–113, 2012. View at Publisher · View at Google Scholar · View at Scopus
  183. I. Dikiy and D. Eliezer, “Folding and misfolding of alpha-synuclein on membranes,” Biochimica et Biophysica Acta—Biomembranes, vol. 1818, no. 4, pp. 1013–1018, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. H. Chaudhary, A. N. D. Stefanovic, V. Subramaniam, and M. M. A. E. Claessens, “Membrane interactions and fibrillization of α-synuclein play an essential role in membrane disruption,” FEBS Letters, vol. 588, no. 23, pp. 4457–4463, 2014. View at Publisher · View at Google Scholar · View at Scopus
  185. C. R. Bodner, A. S. Maltsev, C. M. Dobson, and A. Bax, “Differential phospholipid binding of α-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy,” Biochemistry, vol. 49, no. 5, pp. 862–871, 2010. View at Publisher · View at Google Scholar · View at Scopus
  186. A. N. D. Stefanovic, M. M. A. E. Claessens, C. Blum, and V. Subramaniam, “Alpha-synuclein amyloid oligomers act as multivalent nanoparticles to cause hemifusion in negatively charged vesicles,” Small, vol. 11, no. 19, pp. 2257–2262, 2015. View at Publisher · View at Google Scholar · View at Scopus
  187. A. Gonzalez-Horta, “The interaction of alpha-synuclein with membranes and its implication in parkinsońs disease: a literature review,” Natural Product Communications, vol. 10, no. 10, pp. 1775–1778, 2015. View at Google Scholar · View at Scopus
  188. J. Y. Sung, J. Kim, S. R. Paik, J. H. Park, Y. S. Ahn, and K. C. Chung, “Induction of neuronal cell death by Rab5A-dependent endocytosis of α-synuclein,” Journal of Biological Chemistry, vol. 276, no. 29, pp. 27441–27448, 2001. View at Publisher · View at Google Scholar · View at Scopus
  189. B. B. Holmes, S. L. DeVos, N. Kfoury et al., “Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 33, pp. E3138–E3147, 2013. View at Publisher · View at Google Scholar · View at Scopus
  190. A. Madeira, J. Yang, X. Zhang et al., “Caveolin-1 interacts with alpha-synuclein and mediates toxic actions of cellular alpha-synuclein overexpression,” Neurochemistry International, vol. 59, no. 2, pp. 280–289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. S. H. Oh, H. N. Kim, H. J. Park, J. Y. Shin, D. Y. Kim, and P. H. Lee, “The cleavage effect of mesenchymal stem cell and its derived matrix metalloproteinase-2 on extracellular α-synuclein aggregates in Parkinsonian models,” Stem Cells Translational Medicine, 2016. View at Publisher · View at Google Scholar
  192. X. Mao, M. T. Ou, S. S. Karuppagounder et al., “Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3,” Science, vol. 353, no. 6307, Article ID aah3374, 2016. View at Publisher · View at Google Scholar
  193. K. Li, H. Reichmann, and T. Ziemssen, “Recognition and treatment of autonomic disturbances in Parkinsons disease,” Expert Review of Neurotherapeutics, vol. 15, no. 10, pp. 1189–1203, 2015. View at Publisher · View at Google Scholar · View at Scopus